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ABSTRACT 
Skin cancer is the most prevalent cancer diagnosis worldwide. Squamous cell carcinoma 
(SCC) is one of the most common diagnoses. Fortunately, these cancers are rarely fatal if 
detected and treated early on. However, current treatment options can be painful, 
disfiguring and can require long-term treatment courses, resulting in poor patient 
compliance and cancer progression. Since SCC begins as precancerous lesions, an 
opportunity exists for early preventative interventions which this work aims to address. 
We produced stabilized microfibers via centrifugal spinning and UV photocrosslinking 
composed of poly(ethylene oxide) functionalized with cinnamoyl chloride. Curcumin, a 
molecule known for its anti-cancer properties was loaded into the stabilized fibers and 
exhibited sustained release. The dose-dependent effect of free curcumin on A549 cancer 
cells was investigated. This work demonstrates the potential for this system as a 
transdermal delivery device for the treatment of skin cancer. 
Keywords 
Poly(ethylene oxide), cinnamoyl chloride, UV photocrosslinking, microfibers, centrifugal 
spinning, curcumin, transdermal, drug delivery, cancer  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1. INTRODUCTION  
1.1. Motivation  
Skin cancer is the most prevalent cancer diagnosis worldwide [1, 2], affecting 
approximately 2-3 million people annually [3]. Squamous cell carcinoma (SCC), a 
non-melanoma skin cancer is one of the most common diagnoses. Fortunately, these 
cancers are rarely fatal if detected and treated early during its progression. However, 
current treatment options available such as surgery, cryotherapy and topical creams 
can often be painful, disfiguring, require long-term treatment courses and can cause 
local skin reactions. Due to these factors, patient compliance suffers [4], resulting in 
unnecessary cancer progression. Therefore, there exists a need for an effective novel 
treatment option which permits patient compliance and is effective in preventing 
progression of precancerous lesions into an invasive, malignant state.  
Overall, this thesis aims to study the chemical, physical and biological properties of 
photostabilized poly(ethylene oxide)(PEO)-cinnamate fibers as a carrier for curcumin 
to decrease cancer cell survival and proliferation. 
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2. LITERATURE REVIEW 
2.1. Skin, Skin Cancer and Treatment Options 
2.1.1. Skin 
The skin is the largest organ of the body, covering approximately 1.5 - 2 m2 and 
comprises 15 - 20% of the total body weight. There are three main layers of the skin, 
epidermis, dermis and hypodermis (Figure 2.1). The epidermis is the most superficial 
layer, comprised of keratinocytes, stratified squamous keratinized epithelium and 
pigment producing melanocytes. The middle layer is the dermis, consisting mostly of 
connective tissue and the deepest layer is the subcutaneous layer, also known as the 
hypodermis. Skin can be classified as either thick or thin depending on the thickness 
of the epidermal layer, each with distinct functions. Thick skin is present on the palms 
of the hands and the soles of feet, where exposure to friction is the highest. The rest 
of the body covering is thin skin. The epidermis of thin skin is further divided into 4 
layers, starting with the most superficial: stratrum corneum, granular layer, spinous 
layer and basal layer. Each layer is composed of histologically distinctive cell types 
which are used to identify the source pathological conditions. The skin possesses five 
main essential roles: protection, metabolism, sensory, thermoregulation and sexual 
signalling [5]. Although the skin acts as a protective barrier to UV radiation [6], 
excessive exposure, genetic predispositions [7] or a combination, play an additive 
role in the pathogenesis of skin cancers [8]. 
!3
 
Figure 2.1: Structure of the skin, including layers and main cell types. 
2.1.2. Skin Cancer 
Skin cancers are defined as cancers originating from skin and are classified by the 
cells from which they are derived, these can be categorized into two major groups: 
melanoma and non-melanoma skin cancers (NMSCs). The most common subtypes of 
NMSCs are basal cell (BCC) and squamous cell carcinoma (SCC) [1]. Melanomas 
are cancers that originate from melanocytes, whereas BCC and SCC are cancers 
originating from basal cells and squamous cells, respectively. SCC typically begins as 
sun induced skin lesions called actinic keratosis (AK) [9]. A classic model for cancer 
pathogenesis may be used to describe the progression of actinic keratoses into SCC 
[10]. First, a mutation in a gene such a tumour suppressor may result in the 
development of this precursor lesion. Additively, mutations in proto-oncogenes may 
result in increased proliferative capacity leading to neoplastic properties and the 
epidermis
dermis
hypodermis
squamous cell
basal cell
melanocyte
fibroblast
fat cell
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development of invasive SCC [10]. The induction of these mutations for SCC is 
typically from UV exposure, causing thymidine dimer [11] formation in DNA 
resulting in mutations [9, 12].  
Epidemiologically, skin cancers and more specifically NMSCs are the most common 
cancer diagnoses with incidence rising worldwide. Although mention of its incidence 
is often neglected in worldwide cancer reports due to inconsistent reporting to cancer 
registries to obtain accurate estimates [13, 14]. Fortunately, the mortality rate 
associated with NMSCs is low when detected and treated early on during its 
progression. However, current treatment options are accompanied by low patient 
compliance due to visible side effects [15]. As a result of low patient compliance, AK 
have the potential to develop into invasive SCC, a larger economic and health burden. 
An international study on physical perceptions about current treatment options for AK 
revealed a need for research to address the limitations of current therapies in order to 
improve outcomes [15]. 
2.1.3. Current Treatment Options and Side Effects 
In order to reduce rates of SCC, AK lesions must be managed prior to its progression 
into invasive cancer. Several options currently exist to treat AK. However, there does 
not exist a therapy which meets all the needs of the consumer: good efficacy to 
reduce risk of SCC, low risk of adverse effects, few dosages and short treatment time. 
One current option is surgical removal of lesions, but can result in scarring. Other 
common options include topical treatments such as 5-fluorouracil and imiquimod 
creams, which are less invasive but require extended treatment periods, and can lead 
to undesirable local skin reactions (redness, scarring, etc.). Given that these 
treatments require compliance for up to 16 weeks, patients may be required to 
manage these side effects for long periods of time, decreasing the tolerability of the 
treatment. The downfalls of these current treatment options result in patient non-
compliance and ultimately increasing patient risk for developing invasive SCC. 
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Therefore, the options are to develop new drugs or alternatively improve the delivery 
of current drugs with fewer side effects with equivalent effectiveness are required in 
order to prevent NMSC progression in patients with AK. 
Chemoprevention, a promising area in anti-cancer research is the administration of 
dietary or pharmacologic agents to inhibit or reverse carcinogenesis [16, 17]. In 
contrast to typical chemotherapeutics, these products present with lower side effects. 
Chemopreventive agents may be classified based on the stage of interference during 
carcinogenesis. Blocking agents act early on in the progression by inhibiting the 
conversion of cells from a normal to neoplastic state. Alternatively, suppressing 
agents inhibit proliferation and growth during cancer progression [18]. Examples of 
identified chemopreventive agents are vitamin A [19, 20], lycopene [21], grape seed 
extract [22, 23], green tea extract [24, 25] and curcumin [18, 26, 27]. The focus of 
this work will be on curcumin as a chemopreventive. 
2.1.4. Curcumin  
The naturally occurring and active components of Curcuma longa (turmeric) called 
curcuminoids are isolated from the rhizome, the root of the plant, which contains the 
majority of curcuminoids. The turmeric root and spice derived from it have been used 
as food additives, medicines, textile dyeing and cosmetics for over 2000 years [28]. 
Figure 2.2: Structure of curcumin, keto (top) and enol (bottom) tautomers.   
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Curcumin (C21H20O6) [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione] also known as diferuloylmethane and curcumin I is the principal curcuminoid 
and regarded as the most biologically active curcuminoid of turmeric.  This molecule 
exists as keto-enol tautomers as a solid and in solution (Figure 2.2). 
Desmethoxycurcumin (curcumin II), bis-desmethoxycurcumin (curcumin III) and 
cyclocurcumin are additional chemical constituents of curcuminoids which have 
previously been extracted and identified [29, 30]. In general, the composition of 
commercial curcumin contains: ~77% of curcumin I, ~17% curcumin II and ~3% 
curcumin III. Curcumin I, a polyphenol providing the yellow-orange colour is a 
powder that is soluble in ethanol, dimethylsulfoxide and acetone but nearly insoluble 
in water and ether. Curcumin I possesses a molecular weight of 368.37 g/mol and a 
melting point of 183 °C. Commercially available turmeric and curry powders contain 
curcumin however, these is batch to batch variability of the purity as described by 
Tayyem et al. [31], thus it is imperative to determine the purity of curcumin to clearly 
establish a dose-response relationship.  
Anti-Cancer and Chemopreventive Properties of Curcumin in vitro and in vivo 
It has been demonstrated that curcumin interacts with many cellular targets including 
transcription factors, enzymes and growth factor receptors, ultimately resulting in 
altered gene expression and imparting antioxidant, anti-inflammatory and anti-cancer 
properties (Table 1). Molecules identified as chemopreventive agents are defined by 
their ability to arrest progression or prevent cancer development and have several 
commonalities including enhanced apoptosis, growth inhibition and proliferation, 
halting cellular invasion and inhibition of angiogenesis. 
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Table 1: Summary of curcumin’s cellular targets [32] 
General 
category
Target Function of target/
Observation in 
cancers
Effect of curcumin
Transcription 
factors
Nuclear factor kappa 
B (NF-κB)
Suppresses apoptosis 
and is constitutively 
expressed in many 
cancers
Inhibits the activation 
of NFκB
Activating protein-1 
(AP-1)
Involved in 
proliferation and is 
constitutively 
expressed in many 
cancers
Inhibits activation of 
AP-1
Peroxisome 
proliferator activated 
receptor gamma 
(PPAR-ɣ)
Inhibits proliferation 
of nonadipocytes
Activates PPAR-ɣ 
inhibiting cell 
proliferation, inducing 
apoptosis 
Notch-1 Maintains balance 
between cell 
proliferation, 
differentiation and 
apoptosis. Balance 
disrupted in cancer
Reduces levels of 
Notch-1
Wnt/beta-catenin Highly regulated 
signaling pathway. 
Often dysregulated in 
cancers
Inhibits pathway 
through reduction of 
nuclear β-catenin
Enzymes Cyclooxygenase 
(COX-2)
Inflammatory enzyme, 
overexpressed in 
many cancers 
resulting in cell 
proliferation and 
inhibition of apoptosis
Inhibits expression of 
COX-2
Matrix 
metalloproteinase 
(MMP)
Mediators of tumor 
metastasis, often 
upregulated in cancers
Inhibits MMP-9
Growth factors 
and receptors
Epidermal growth 
factor receptor 1 
(EGFR1)
Overexpressed in 
cancer
Inhibits expression, 
act as EGFR1 
antagonist
Fibroblast growth 
factors (FGFs)
Overexpressed in 
cancer and involved in 
angiogenesis
Angiogenic pathway 
inhibited 
Vascular endothelial 
growth factor (VEGF)
Major role in 
angiogenesis and 
cancer growth
Inhibits expression of 
VEGF
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Safety and pharmacological effects of oral curcumin 
Curcumin is remarkably non-toxic and is well tolerated even at doses as high as 12 g/
day [33]. However, due to its hydrophobicity, water insolubility and first pass 
metabolism, it has poor oral bioavailability. Orally is the most common and 
convenient route of drug administration. In order for the drug to reach the systemic 
circulation it must first be absorbed by the intestinal epithelium and enter the hepatic 
portal system where first pass metabolism occurs. After which, drug concentrations 
are dramatically reduced due to metabolism in the liver and the remaining dose may 
finally be able to enter the systemic circulation to exert their effects [34]. Studies [33, 
35] conducted to investigate oral dose-serum concentration relationships showed that 
curcumin and its metabolites are detectable in serum with curcumin doses greater 
than 4000 mg/day with a respective maximum serum concentration of 0.5±0.11 µM. 
This serum level peaked one to two hours following oral intake and declined within 
12 hours. Doses below 4000 mg/day were undetectable in serum. The anti-cancer 
properties of curcumin are most pronounced in and near the gastrointestinal tract 
when orally administered and are most effective against cancers of such tissues. 
Garcea et al. [34] suggest that although curcumin is an effective chemopreventive 
agent in vitro, the oral dose required for concentrations with effective 
pharmacological activity are likely not feasible in humans. These studies provide a 
thorough investigation into the poor oral bioavailability of curcumin. Thus, there is a 
need for improved delivery to maximize the benefits for this effective 
chemopreventive agent.  
Curcumin as an iron chelator in vivo 
An unexpected observation made by Jiao, Y. et al. [36] revealed the modulation of 
iron metabolism of liver cells in vitro suggestive of curcumin’s ability to chelate iron. 
Two main proteins were investigated, ferritin and glutathione S-transferase (GSTα). 
Ferritin is a protein which maintains intracellular iron levels and a decrease in ferritin 
levels indicates lowered intracellular iron. GSTα is a cytoprotective enzyme which is 
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induced in parallel with ferritin transcription and regulates ferritin levels. In this 
study, liver cells were cultured in the presence of curcumin and the effects on ferritin 
and GSTα were measured. Curcumin induced GSTα and ferritin mRNA levels but 
reduced detected levels of ferritin protein. To further study this phenomena, mice 
were fed diets supplemented with curcumin for 12 weeks. Studies revealed a 
statistically significant reduction in ferritin protein levels and increase in GSTα levels 
in mice receiving 2% curcumin as compared to controls receiving 0% curcumin in 
their diets. This reduction in ferritin levels suggest reduction of intracellular iron 
levels and thus iron chelating ability of curcumin. Jiao, Y. et al. [36] further studied 
the impact of curcumin as an iron chelator on systemic iron levels and its impact on 
iron deficiency conditions. In this study, mice were fed diets containing various 
concentrations of iron ranging from 5 - 1000 mg/kg to establish the dose-dependent 
parameters of systemic iron such as plasma iron, hemoglobin, hematocrit levels and 
others were measured. Mice from all groups showed no statistically significant 
differences in such parameters. Subsequently, mice were fed diets supplemented with 
curcumin at concentrations ranging from 0 - 2% to study the effect of curcumin on 
mice receiving different amounts of iron in their diets. For mice receiving curcumin 
with diets containing low-iron, a significant decrease in all parameters of systemic 
iron was observed, suggesting iron deficiency anemia was induced by curcumin. 
Microcytosis, a decrease in red blood cell size indicative of anemia, was found for 
mice receiving diets containing low-iron with microcytosis increasing proportionally 
with amount of curcumin intake[37]. 
  
At this point, curcumin has the potential to chelate iron and alter systemic iron 
metabolism as demonstrated by studies in vitro and in vivo. Thus oral administration 
of curcumin may be harmful in patients with diminished iron stores due to diet, 
anemia or other chronic diseases. Anemia is prevalent in patients with cancer [38] and 
thus, orally administered curcumin may be particularly harmful in large doses to 
those patients. Although a study comparing oral versus topical curcumin in a skin 
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cancer model reported equivalent efficacy, localized treatments may be preferred over 
oral to avoid iron chelation complications. 
Topical administration of curcumin 
A method of drug administration that would avoid low oral bioavailability and 
potential of iron chelation in vulnerable populations would be possible in cases where 
local delivery of curcumin could be accomplished. One such example is externally on 
the skin. Curcumin’s activity in preventing the progression of cancer was initially 
demonstrated with mice. Mice were treated with 12-O-tetradecanoylphorbol-13-
acetate (TPA), a known inducer of skin cancer, with co-treatment of a topical 
curcumin paste. The effects of TPA were inhibited due to curcumin’s inhibitory effect 
on cyclooxyrgenase activities [39]. Other studies using curcumin cream pastes note 
that the creams were irritating in nature causing thickening of the epidermis. This 
issue may be augmented in humans as side effects are one of the main causes of poor 
patient compliance [40, 41]. Therefore, although topical administration is preferred 
for some applications, there does not exist a carrier without side effects.  
2.2. Drug Delivery 
Drugs are of significant importance in treating diseases. One category is the 
chemotherapeutic drugs, a class of drugs used to treat cancer. Typically the mode of 
administration is intravenously and less commonly, orthotopic injection into specific 
sites such as the spine, by mouth as a pill or liquid or topically as a cream. Side 
effects of chemotherapy may be severe as a result of normal cell death along with 
cancer cell death. Typically, chemotherapeutic drugs are non-specific and systemic 
introduction into the body is the main cause of side effects [42]. Thus, targeting drug 
activity by either exploiting key differences between cancer and healthy tissues or 
localizing drug delivery is of clinical importance.  
The major advantage of administering drugs using a drug delivery system is the 
maintenance of drug concentrations within the therapeutic range (Figure 2.3). 
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Minimizing general exposure to these compounds is ideal, however, in order to 
maintain effective concentrations, smaller, more frequent administrations would be 
required and risk increasing plasma drug levels into the toxic range. Both 
inconvenience and side effects result in poor patient compliance and decrease quality 
of life. Thus, controlled drug delivery to maintain safe, effective concentrations is 
highly desired. 
Figure 2.3: Drug concentration following drug administration with (solid line) and 
without (dashed line) controlled release. 
Drug delivery systems (DDS) may be classified by the mechanism of release they 
follow: solvent activated, chemically controlled and diffusion controlled [43]. Briefly, 
solvent activated systems are osmotically or swelling controlled. In osmotically 
controlled systems, an external fluid moves against the drug concentration gradient, 
forcing the drug out of the device. This system works for water-soluble drugs and 
zero-order kinetics are possible. In swelling controlled systems, drugs are dispersed in 
a dry hydrophilic polymer and swell once they encounter an aqueous environment 
such as body fluids resulting in diffusion of drug out of the polymer. Chemically 
controlled delivery systems are further classified as biodegradable or pendant-chain. 
Biodegradable systems release the drug as the polymer disintegrates. Pendant-chain 
systems have drug molecules chemically bound to the polymer chains with release 
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dependent on cleavage of that bond. Diffusion controlled DDS can be further 
classified into reservoir or monolithic devices. In reservoir devices, the polymer 
surrounds a core of drug where release occurs by diffusion through the polymer 
membrane. This type of release can be described using Fick’s first law (equation 1) if 
the membrane is non-porous. Where J is the flux/unit area, D is the diffusion 
coefficient through the membrane, K is the partition coefficient, ΔC is the 
concentration difference across the membrane and l is the thickness of the membrane. 
Monolithic devices have the drug uniformly dispersed throughout an inert (non-
swollen or fully swollen, and non-degrading) polymer and release is controlled by 
diffusion of the drug from the polymer matrix. Cumulative amount of drug released 
can be calculated for a thin slab using early (equation 2) and late (equation 3) time 
approximation equations. Where Mt is the amount of drug released at time t, M∞ is 
the amount of drug loaded, D is the diffusion coefficient and l is the thickness of the 
slab.  
 
Cylindrical and spherical geometries require additional parameters in the calculations 
(equations 4 and 5). Release of a drug from these geometries can also be calculated 
using early time approximation and late time approximation. Parameters are the same 
as above, in addition to those, a is the radius of the cylinder or sphere. These 
equations were described by Baker and Lonsdale[44]. 
(1)
(2)
(3)
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Many applications of these drug delivery systems exist on the market today. Some 
examples of diffusion controlled drug delivery devices include, Progestasert® a 
reservoir DDS which releases progesterone and acts as an intrauterine contraceptive. 
Drug eluting stents are coated in a drug-containing polymer is an example of a 
monolithic DDS. Transdermal patches are polymer DDS that adhere to the skin, these 
systems are designed to be either reservoir or monolithic. An example is the 
NICODERM® patch manufactured by Johnson and Johnson.  
A potential drug for delivery is curcumin, it is selective in its apoptotic and non-
proliferative effects. This is due to the phenotype of tumour cells. Firstly, it has been 
shown that tumour cells have increased uptake of curcumin [45], thus localizing its 
effects. Secondly, many tumour cells have constitutively activated NF-κB, a complex 
that regulates DNA transcription, which can result in cells proliferating 
uncontrollably. Curcumin acts to inhibit this over-activation, thus reducing 
proliferation [46]. Additionally, glutathione acts to reverse the inhibition of NF-κB by 
curcumin which would allow for proliferation. Lower levels of glutathione in tumour 
cells compared to healthy cells reduces that ability [47]. This selective capability 
would provide an additional means of targeting activity against tumour cells.  
2.3. Common Fiber Production Methods 
There is an extensive list of fiber production methods [48] which use a combination 
of principles covered below. However, for the purpose of this work, a brief summary 
of three methods will be covered with a focus on centrifugal spinning. Many of these 
(4)
(5)
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methods have been used for biomedical purposes such as tissue engineering and drug 
delivery.  
2.3.1. Extrusion Fiber Production 
Formation of fibers via extrusion require polymers to be in a viscous liquid state, 
typically achieved through melting for thermoplastic or by dissolving in a solvent for 
non-thermoplastic polymers. The liquid is then forced through a spinneret which 
contains pores, to form fibers. There are three main types of extrusion fiber 
formation: wet spinning, dry spinning and melt spinning. Wet spinning, uses solvents 
to both dissolve the polymer prior to extrusion and then to precipitate the fiber post-
extrusion. Dry spinning, in contrast to wet spinning uses air or an inert gas to 
evaporate the dissolving solvent post-fabrication, resulting in solidification. Melt 
spinning, as its name suggests, is the melting of a thermoplastic polymer and cooling 
of the polymer post-fabrication which results in fiber solidification[48].  
Melt spinning is unique in that it does not require the use of solvents. The use of 
solvents in some spinning methods carry concerns related to environmental impact, 
toxicity of final product and a decrease in productivity and efficiency of the overall 
process. Without the use of solvents in melt spinning the concern for solvent-related 
toxicity for biomedical applications and requirement of polymer solution 
concentration optimization for spinnability is eliminated, a notable advantage. 
Additionally, the solidification of fibers after extrusion involve a one-way heat 
transfer, a rapid process resulting in high production rates, in comparison to solution 
spinning which requires evaporation, a mass transfer which is less efficient [48]. 
Some biomedical applications of extruded fibers include, extruded collagen fibers as 
a scaffold for tissue engineering [49], microextruded polyesters for tissue engineering 
scaffolds and controlled drug delivery applications [50] and synthetic sutures that are 
extruded polymers which are sometimes further processed by braiding. 
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2.3.2. Electrospinning Fiber Production 
Production of fibers via electrospinning involves polymers dissolved in an 
appropriate solvent which is fed through a needle with flow controlled by a syringe 
pump. A droplet is formed at the tip of the needle which is held in place by its surface 
tension. With an applied voltage between the needle and a grounded collector plate 
located some distance away from the needle, a charge is induced within the droplet. 
These charges repel each other within the droplet and at a critical point, this force will 
overcome the surface tension holding the droplet in place and a distortion, termed 
Taylor cone will form and a jet will exit this cone to form fibers. The fibers will travel 
towards the collector and while the solvent evaporates, the fiber undergoes a 
whipping motion resulting in elongation and a fiber diameter decrease. This method 
has several processing parameters which may be modified in order to optimize the 
fiber morphology desired. These include: needle-to-collector distance, viscosity of 
solution, polymer concentration, applied voltage, solution flow rate, electrical 
conductivity and the temperature and humidity of experimental space. These 
parameters allow for tailoring of fiber morphology. Diameters of fibers produced 
from this method range from tens of nanometers up to micrometers. These fibers have 
a large surface to volume ratio, an ideal property for many applications. 
Examples of electrospun fibers used in the literature for biomedical applications 
include tissue engineering scaffolds for bone [51], neural [52], vascular [53] as well 
as other tissues. The versatility of electrospinning allows for a variety of materials to 
be spun into random and aligned fibrous mats. Electrospun fibers have also 
demonstrated utility as drug carriers, for example anti-virals were incorporated into 
electrospun cellulose acetate phthalate fibers as a means to deliver the drug and 
prevent transmission of the human immunodeficiency virus [54].  Electrospun fibers 
are of interest in manufacturing wound dressings given the potential of nanofiber 
mats mimicking the native extracellular matrix (ECM) structure of skin, encouraging 
innate repair systems to generate ECM components and encouraging repair of the 
!16
wound. In combination with the structure of the fibers, impregnation of drugs may 
further encourage repair through preventing infection with antibacterials or 
therapeutic agents known to improve repair [55]. Materials such as cellulose acetate 
phthalate [54], poly(lactic-co-glycolic acid) (PLGA) [56], and poly(caprolactone) 
(PCL) [57, 58] have been used for these applications. 
2.3.3. Centrifugal Melt Spinning Fiber Production 
Centrifugal melt spinning has been used for over 100 years in the form of a sugar 
spinning apparatus, also known as a cotton candy machine. It was invented and 
patented in 1897, at that time called an “electric candy machine” and in 1904, cotton 
candy was introduced at the St. Louis World Fair. Since 1897, cotton candy 
production has been rather unchanged [59]. Sugar is loaded into a reservoir made of a 
heat conductive material where it is melted, the reservoir contains small openings 
called orifices. The term spinneret is used to label the reservoir and its orifices 
(Figure 2.4).  
Figure 2.4: A general schematic of a spinneret illustrating the reservoir, orifices and 
the mounted shaft.  
The spinneret rotates about its axis, above a heating element which melts the loaded 
material, fibers leave the orifice and are collected. The centrifugal force due to the 
rotation forces the material to exit the orifices and as that force overcomes the surface 
reservoir
orifice
shaft
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tension of the material at the orifice a polymer jet is forms, the fiber solidifies rapidly 
in the air and deposits onto the collector. 
This rapid method of fiber production has been utilized by a relatively small number 
of research groups. Badrossamay et al. [60] first published their work in 2010 using 
the principles of a cotton candy machine to solution spin nanofibers. They termed the 
method rotary jet spinning (RJS). This method was able to produce aligned 
poly(lactic acid) (PLA) nanofibers ranging from 50-3500 nm in diameter for the 
guidance of rat cardiomyocytes. The range of fiber diameters produced was wide and 
dependent on the rotation speed of the spinneret. In 2014, the group published work 
with polymer-protein hybrid, poly(caprolactone)(PCL) and collagen or gelatin. This 
work utilized the same fiber production method (RJS) and were successful in 
producing highly aligned nanofibers for the purpose of influencing cell migration 
[61]. Since then, this method has become of increasing interest in the field for tissue 
engineering [58] and this interest may be further increased with the availability of a 
commercial centrifugal spinning machine from the company FibeRio, based on the 
patented Forcespinning ® technology for producing nanofibers [62]. One of the main 
advantages of a centrifugal fiber production method is the low cost and high yield 
[63]. Although there are some limitations associated with this method such as 
constraints due to the materials’ properties resulting in variable fiber quality and 
morphology [48]. An additional limitation is the ability to align the fibers has been 
shown to be unidirectional. However, it has been noted that for tissue engineering 
applications, control of lamination to mimic native extracellular matrices is highly 
sought after [64] and this has not been demonstrated with centrifugal spinning. 
2.4. Materials for Fiber Spinning 
Various materials have been used for fiber spinning with applications ranging from 
textiles and insulation to the biomedical industry, of which biomaterials are a major 
component. Biomaterials encompass materials which are in contact with biological 
systems. There are various polymer options for these materials which may be tuned to 
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have appropriate chemical, physical and biological properties. Proper selection of 
appropriate polymers and modifications are essential to a biomaterials’ performance. 
For example, a biomaterials’ surface topography, size and shape can affect the host 
response and if mismatched, can result in infection, fibrosis and poor performance of 
the material. 
2.4.1. Polymers 
The use of natural polymers for biomaterials possesses the advantage of 
biocompatibility and bioactivity due to their innate function in the body, these 
materials include collagen, chitosan and silk fibroin. In particular, collagen forms the 
extracellular matrix of many tissues in the body, aiding in the maintenance of 
structural integrity and playing an integral role in cell signalling. Collagen has been 
used to produce fibers for tissue engineering applications. These fibers possess many 
attractive properties including: low antigenicity, good cell compatibility, low 
cytotoxicity and biodegradability. However, a downfall of collagen is the low 
availability of human sources. Most commonly used collagen sources are porcine, 
bovine and equine. The use of non-human collagen may lead to deficiencies in 
biomaterial performance due to the heterogeneity, untraceable origins, the possibility 
of disease [65] or immunological stimulator transmittance [66]. Recently, the advent 
of human recombinant collagen production provides the possibility of using human-
only sources for applications [67].  
Alternatively, synthetic polymers are often used in biomedical research given their 
availability and  potential for simple modification and functionalization. They can be 
categorized broadly into hydrophilic and hydrophobic polymer based on the 
properties of their monomer units. Common hydrophobic polymers used for 
biomedical applications include, poly(caprolactone) (PCL), poly(ester amide) (PEA) 
and polydimethylsiloxane (PDMS). Common hydrophilic polymers are poly(ethylene 
glycols)(PEG), poly(ethylene oxide)(PEO) and poly(vinyl alcohol)(PVA). 
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Another consideration about polymers is their hydrophilicity. Hydrophilicity of a 
polymer is determined by the functional groups it possesses such as hydroxyls, 
carboxyls, carbonyls, amines and amides and their interaction with water molecules 
through hydrogen bonding. Increased hydrophilicity will result in increased and 
stronger interactions with water and swelling of the material resulting in changes in 
mechanical and chemical properties [68]. Effects due to the hydrophilicity of a 
material can influence cell adhesion [69], increase water absorption, have anti-fouling 
properties[70] and enhance drug solubility and thus drug delivery. 
2.4.2. Poly(ethylene oxide) 
Poly(ethylene oxide) (PEO) is a synthetic crystalline, thermoplastic and water-soluble 
polyether compound (Figure 2.4), these compounds are called poly(ethylene glycol) 
(PEG) or PEO depending on their molecular weight, PEO for the higher molecular 
weights. The threshold for naming varies in the literature with values of 10 000 g/mol 
[71] and 25 000 g/mol [72] reported. PEG and PEO are commonly used for 
biomedical purposes as a conjugate for increasing solubility of hydrophobic drugs 
[73], coating of materials to prevent protein adsorption and opsonization [74] which 
could stimulate the immune system and result in immune system attack and immune 
rejection. These applications exploit the hydrophilicity of PEG and PEO to avoid 
these complications.  
Figure 2.5: Chemical structure of PEG and PEO, where n is the number of monomer 
units. 
Many modifications of PEO have been studied in the field of biomedical engineering. 
With hydroxyl end groups and high solubility in organic solvents, end-group 
modifications are relatively simple and the polymer may undergo a variety of 
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reactions. Copolymerization of PEO to other polymers to impart distinct properties 
such as flexibility and hydrophilicity has been shown to be effective [75]. Imparting 
properties of PEO may allow for materials typically involved in protein adsorption to 
resist such interactions and reduce the risk of   undesirable biological responses such 
as clotting [76]. In addition to copolymerizing PEO in a linear fashion, PEOs have 
been polymerized in star shapes [77, 78], a form of branching. The ability to tailor the 
shape of polymer branching allows for tuning of properties such as viscosity [79], 
porosity of constructs [78] and stimuli-sensitivity [80] for the desired application. 
PEO is a versatile, FDA approved polymer currently used in cosmetic and 
pharmaceutical products [81, 82] due to its non-toxicity and effective clearance 
through urinary and fecal excretion [75].  
2.5. Crosslinking Options for Polymers 
Water-soluble polymer fibers such as PEO fibers must undergo post-processing 
modification to stabilize them in aqueous environments such as body fluids. 
Intermolecular bonds may be formed in order to create insoluble networks. The 
degree of crosslinking which is related to stability and biodegradation may be tailored 
depending on the particular application. 
2.5.1. Methods of Crosslinking  
The two main methods for crosslinking of polymers are chemical and physical. 
Chemical crosslinking involves the addition of a chemical group to join molecules 
together.  Examples include genipin which may react with amine groups of proteins 
such as collagen [83] and polysaccharides such as chitosan [84]. Similarly, 
glutaraldehyde and formaldehyde react with hydroxyls of many different polymers 
and link molecules together through those newly formed covalent bonds. Physical 
crosslinking methods use the addition of energy through changes in temperature such 
as thermal cycling, through UV light for photocrosslinking and also through high 
energy ionizing radiation such as ion beam implantation or x-ray which form free 
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radicals which reform into crosslinks. Physical crosslinking is often preferred for 
biomedical applications as they do not introduce new chemicals into the final product. 
However, chemical crosslinking methods are highly effective and if removal of free 
reagents is possible and the byproducts of degradation are non-toxic this method is 
useful [85].  
2.5.2. Photochemical Crosslinking 
For this work, the use of photochemical crosslinking was employed. This method 
involves the addition of a chemical group to render the polymer sensitive to UV light. 
After the addition of this carbon-carbon double bond, the exposure to UV light results 
in radical formation and bond reformation between functionalized chains resulting in 
a network of crosslinked molecules (Figure 2.6) [86]. A downside of this method is 
the requirement of two separate steps, functionalization followed by 
photocrosslinking with UV irradiation. However, a benefit would be the ability to 
tune both the extent of functionalization as well as length of irradiation time to tune 
the degree of crosslinking. 
Figure 2.6: Proposed crosslinked molecule of PEO-cinnamate after UV irradiation. 
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2.5.3. Cinnamoyl Chloride 
Cinnamate functionalized polymers have been used extensively for biomedical 
research purposes. Photocrosslinking of electrospun fibers post-production [87] and 
in situ during electrospinning have been performed [88]. Cinnamate modified 
polymers have been shown to undergo UV crosslinking via [2+2] photocycloaddition 
[86]. As an acid chloride, cinnamoyl chloride is a highly reactive molecule in 
comparison to its carboxylic acid counterpart due to the chloride being an excellent 
leaving group and will readily undergo nucleophilic reactions. This allows for 
efficient functionalization of polymer end-groups. Reactions involving cinnamoyl 
chloride should be performed under dry conditions given that cinnamoyl chloride is 
highly reactive with water and would render the molecule less reactive once 
converted to cinnamic acid.  
Cinnamic acid has a natural origin, and is widely present in the plant kingdom, in 
particular in the essential oils of basil and cinnamon [89]. Cinnamoyl chloride, 
modified from cinnamic acid is typically used to functionalize polymers, there is 
potential for cinnamic acid to form during ester hydrolysis of the crosslinks. 
Fortunately, there is no evidence to support that this molecule possesses a toxic threat 
[89, 90]. Cinnamoyl chloride has been shown to have low toxicity as it is 
spontaneously metabolized in the body [91]. And is thus a good option for 
crosslinking water-soluble polymers for biomedical applications. 
2.6. Assessment of Delivery Systems 
2.6.1. Drug Efficacy and Cell Compatibility 
Evaluation of a drug's effectiveness as delivered from the drug delivery device is an 
integral step in demonstrating design and production accomplishments.  
Determination of a drug’s efficacy is typically performed prior to the design of a drug 
delivery device as DDS are used to improve on pre-existing drugs. Tests performed to 
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evaluate a drug’s performance include assays to determine the effective 
concentrations (EC) for agonists and inhibitory concentrations (IC) for antagonist 
drugs. EC50 and IC50 values are defined as the drug concentrations that exhibit 50% 
of in vitro response (Figure 2.7). These values may be used in the classification of 
drugs for their potency and the plots of activity may be guidelines for dosing. 
Figure 2.7: Definition of IC50/EC50 graphically, drug concentration at 50% activity 
is defined as the IC50/EC50 
The selection of an appropriate cell line involves the consideration of several 
variables such as the cell species as some studies are species-specific and also the 
functional characteristics of interest for the experiment such as surface and 
intracellular targets. For testing of pharmacological agents, understanding the cellular 
targets of the drug may guide selection of the cell line for testing. For study of cancer 
cells in particular, the source of the cells is not the only variable to consider given that 
cell lines mutate and do not necessarily represent the cancer from which it was 
sourced as a whole. Selection of cell lines based on cellular targets and ensuring the 
drug acts on those targets will provide valuable information for translating into in 
vivo studies. Cancer cell lines do not necessarily represent the heterogeneity of 
tumours and thus a gap exists between in vitro studies and clinical samples [92]. 
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2.6.2. Appropriate Evaluation of Transdermal Drug Delivery 
In addition to evaluating DDS in vitro, studies with appropriate animal models is 
integral prior to clinical studies. The purpose of animal studies is to evaluate the 
efficacy and safety of the proposed system. Focusing on transdermal drug delivery, 
the assessment of delivery through the skin is a major step in evaluating the system. It 
is nearly impossible to assess skin permeation using just one assessment either in 
vitro, in vivo or ex vivo [93]. Thus, a combination of these experiments is required for 
effective demonstration of delivery. For these assays, human skin is the most relevant 
for study, however availability may be limited. An animal model that is appropriate 
for study will have similar structures when compared to human skin, possessing 
similar density of hair follicles, thickness of epidermis and dermis. Animal models 
suggested include primate, porcine, snake and rodent. For some of these animals, 
considering a hairless counterpart maybe be beneficial as they are better 
representations of humans [93]. 
In addition to studying drug permeation, animal models with representative disease 
states will be of importance to demonstrate the drug permeation and activity of the 
drug. For skin cancer, nude rodent models with established protocol for inducing UV 
skin damage have been proposed [94]. 
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3. HYPOTHESIS AND OBJECTIVES 
3.1. Hypothesis 
Firstly, we hypothesize that poly(ethylene oxide) (PEO), a biocompatible polymer can 
be modified and processed into stabilized microfibers. Since PEO is water-soluble 
and the fibers will be in contact with bodily fluids, aqueous stability must be imparted 
through crosslinking using cinnamoyl chloride (CC), a highly reactive acyl chloride 
to introduce an ultraviolet (UV) sensitive double bond to the polymer for 
photocrosslinking. Secondly, we hypothesize that these stabilized fibers will be able 
to carry and deliver curcumin at a sustained level sufficient to inhibit cell 
proliferation and promote cell death. 
 3.2. Objectives 
This work aims to study the potential of a crosslinked polymeric fiber system for 
carrying and delivering curcumin and demonstrating the efficacy of curcumin on a 
cancer cell line. The main objectives of this work are to: 
1. Synthesize an ultraviolet (UV) sensitive polymer by functionalizing 
poly(ethylene oxide) (PEO) with cinnamoyl chloride. 
2. Using this bulk material to produce microfibers using centrifugal melt spinning. 
3. UV irradiation of the fibers to crosslink the polymer at cinnamoyl moieties. 
4. Investigate curcumin loading and release from crosslinked, stabilized fibers. 
5. Study the effects in vitro of free curcumin and curcumin from loaded PEO-
cinnamate fibers.  
Ultimately the goal is that centrifugal melt spun PEO-cinnamate fibers will carry and 
release curcumin locally at the site of precancerous lesions. 
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4. MATERIALS AND METHODS 
4.1 Materials 
Table 2: Materials for experimental procedures 
4.2. Synthesis: Functionalization of Poly(ethylene) oxide 
with Cinnamoyl Chloride 
100 g (2.857 mmol) of PEO was frozen in a -20 °C freezer then subsequently 
lyophilized. The samples were freeze-dried for 18 hours at 0.04 mbar at -180 °C. 
Lyophilized PEO was dissolved in 400 ml of dry DCM under stirring. An additional 
300 ml of molecular sieve dried DCM was added. Next, 3.5 ml (0.035 mmol) of dry 
pyridine was added. Subsequently, 5 g (30 mmol) of cinnamoyl chloride was added 
Material Supplier Detail Item Number
Poly(ethylene 
oxide)
Sigma Aldrich 35 000 g/mol 25322-68-3
trans-Cinnamoyl 
chloride
Alfa Aesar 97% purity 17082-09-6
Curcumin Sigma Aldrich ≥94% curcuminoid 
content
458-37-7
Anhydrous ethyl 
alcohol
Commercial 
Alcohols
99.8% Lot # 018568
Dichloromethane Solvent purification 
system, Dept. of 
Chemistry, UWO
Pyridine Sigma Aldrich Anhydrous, 99.8% 270970
Phosphate 
Buffered Solution
Sigma Aldrich Tablets P4417
AMEM-alpha Wisent Inc. + 10% FBS 310-022-CL
Trypsin-EDTA Wisent Inc. 0.25% trypsin 325-043-EL
Phosphate 
Buffered Solution
Gibco (-) CaCl2, MgCl2 10010-023
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and the reaction vessel was covered entirely with aluminum foil to protect from 
photo-damage. The reaction proceeded under the following conditions: room 
temperature, constantly stirred at 400-600 RPM and under a N2 atmosphere for 
approximately 24 hours. After which, PEO-cinnamate was precipitated, 2 L of diethyl 
ether was used to precipitate each 100 ml volume of PEO-cinnamate dissolved in 
DCM. The solution of of DCM and PEO-cinnamate was manually poured, slowly, 
into a beaker of magnetically stirred diethyl ether (500 RPM). The precipitate was 
then isolated using vacuum filtration and desiccation at room temperature for a 
minimum of 48 hours, covered entirely with aluminum foil to protect from potential 
photo-damage. PEO-cinnamate remained under house vacuum until further 
processing was required. The synthesized product along with the reactants, PEO and 
cinnamoyl chloride then underwent differential scanning calorimetry (DSC), Fourier 
Transform Infrared Spectroscopy (FTIR) and proton nuclear magnetic resonance (1H-
NMR) for characterization. 
4.3. Chemical Characterization 
4.3.1. DSC 
Differential scanning calorimetry (DSC) analysis of cinnamoyl chloride, PEO and 
PEO-cinnamate was performed using a TA instruments Thermal Analysis DSC at a 
heating rate of 10 °C/min under nitrogen. The melting points were determined from 
the second heat scan at the peak point of the thermograms. 
4.3.2. FTIR 
A Bruker spectrophotometer was used to obtain FTIR spectra of solid samples of 
cinnamoyl chloride, PEO, PEO-cinnamate and crosslinked PEO-cinnamate with and 
without curcumin. 
4.3.3. 1H-NMR 
1H-NMR analyses of cinnamoyl chloride, PEO and PEO-cinnamate were performed 
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using a Varian Inova 600 spectrophotometer. Spectra were obtained in CDCl3 at 600 
MHz. The percentage of functionalized PEO was determined my integration of signal 
strengths at 3.65 ppm and 6.50 ppm associated with PEO non-hydroxyl hydrogens 
and cinnamate alkene hydrogen adjacent to the ester, respectively.  
4.4. Centrifugal Melt Spinning 
Fibers were produced using a modified cotton candy machine (Sanrio, Hello Kitty, 
Model: #APP-96209) shown in Figure 4.1. The cotton candy machine was modified 
with the replacement of the motor, with a 250 W brushless DC motor and EPOS2 
70/10 controller purchased from Maxon Motor (Switzerland). Additionally, a 48 V, 
600 W power supply from Mean Well (USA) was added. Fibers were produced with 
the as-purchased system as well as with modifications and designed spinneret (Figure 
4.2). 
Figure 4.1: Hello Kitty Cotton Candy Machine as-purchased with first batched of 
spun sugar (left). Spinneret of as-purchased system (right). 
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Figure 4.2: New spinneret design for the modified cotton candy machine. 
4.5. Fiber Characterization and Image Analysis 
4.5.1. Scanning Electron Microscopy  
A Hitachi S-3400N variable pressure scanning electron microscope was used to 
obtain high resolution images. Nine locations were pre-selected using accompanying 
software to allow for consistency between samples. An accelerating voltage of 10 kV 
and working distance of 21 - 25 mm was selected. 
4.5.2. Image Processing 
ImageJ was used to measure and collect fiber diameters from SEM images. Scale bars 
located at the bottom right corner of each SEM image was used to calibrate the 
measurement tool and fiber diameters were measured perpendicularly to fiber edges. 
4.6. UV Crosslinking and Characterization 
4.6.1. UV Irradiation 
PEO-cinnamate fiber samples were irradiated by with UV for various lengths of time 
at a distance of 5 cm from the light source (Figure 4.3). UV/Vis was performed as 
described below. 
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4.6.2. UV/Vis  
A Beckman Coulter DU520 General UV/Vis spectrophotometer was used to obtain 
UV/Vis spectra. Fiber samples were suspended in deionized water in a quartz cell and 
thin films were cast onto quartz slides and dried prior to measurements for UV-
crosslinking studies. Absorbances at λ=277 nm were obtained. 
Figure 4.3: UV lamp for sample photocrosslinking with shelf set at 5 cm from lamp. 
4.7. Curcumin Loading and Characterization 
4.7.1. Loading Procedure 
Crosslinked PEO-cinnamate fibers were covered with 5 ml of an ethanol and 
curcumin solution and allowed to soak for 24 hours. After which, samples were 
centrifuged at 6000 RPM for 15 minutes, the supernatant was removed and fibers 
were washed with a series of water and EtOH solutions, diH2O x 1, 50% ethanol/
diH2O x 1 and diH2O x 1, after each wash, samples were centrifuged at 6000 RPM 
for 5 - 10 minutes. After the final water wash and supernatant removal, remaining 
diH2O was left with the fibers overnight. After 24 hours, diH2O was added for a final 
wash prior to release studies. 
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4.7.2. Loading Efficiency 
Curcumin loading efficiency was determined by repeatedly washing loaded samples 
in 10 ml of ethanol, centrifugation to isolate fibers until curcumin was no longer 
detectable in the supernatant. The ethanolic supernatant was sampled and analyzed 
using UV/Vis spectroscopy. The values were compared to a standard curve of 
curcumin in ethanol. Absorbances at λ=427 nm were obtained. 
4.8. Curcumin Release 
Loaded curcumin fibers were placed into 5 ml of phosphate buffer solutions (PBS) 
with a pH of ~7. Release was monitored over a period of 14 days. The centrifuge 
tubes were centrifuged at 6000 RPM for 12 minutes, and the supernatant was 
collected at specific time points. Samples were analyzed using UV/Vis spectroscopy. 
4.9. Cell Studies 
4.9.1. Cell Culturing 
A549 human lung carcinoma cells were maintained at 37°C and 5% CO2 in Minimum 
Essential Medium Alpha Medium (AMEM, Wisent Inc.) supplemented with 10% 
fetal bovine serum (FBS, Wisent Inc.). Dose-response curves were determined by 
incubating 1x105 cells/flask (T25, Nunc™ Thermo Scientic) with various 
concentrations of prepared free curcumin solutions with final concentrations in 
culture media of 0, 0.5, 1, 2, 5, 10, 15, 20, 50 and 100 µM for the first trial and 0-10, 
12 and 15 µM for the final two trials. Three replicates were used per treatment group. 
4.9.2. Free Drug Solution Preparation and Measurement 
Curcumin was dissolved in ethanol and serially diluted to achieve the above 
concentrations (4.9.1.). This was completed under non-sterile conditions thus 
sterilization was required prior to treating the cells. Under sterile conditions, solutions 
were subsequently filtered through 0.2 µm syringe filters to remove potential bacteria, 
fungal spores and undissolved particles of curcumin. To ensure accurate 
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concentrations produced after filtering, a volume of curcumin solution was removed 
and UV/Vis spectroscopy was used to measure absorbance and compared to a 
standard curve to determine curcumin solution concentrations.  
4.9.3. Cell Proliferation Determination 
After 72 hours of incubating with free curcumin, media was removed, cells were 
rinsed with PBS, trypsinized with 0.5 ml trypsin-EDTA and diluted with 19.5 ml of 
PBS for cell counting. A Beckman Coulter Counter was used for cell number 
determination. Two counts were performed per flask of cells and the average was 
used. A fresh vial of cells was thawed for the last dose-response experiment.  
4.10. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism™ version 5.0c.  
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5. RESULTS AND DISCUSSION 
This chapter begins with the synthesis and characterization of PEO-cinnamate to 
functionalize PEO with a carbon-carbon double bond for UV photocrosslinking 
(Section 5.1). Cinnamoyl chloride was selected to add a photocrosslinkable functional 
group to the water soluble polymer PEO as it was previously demonstrated to be an 
effective molecule with no known toxic effects [89]. The utility and spinneret 
parameters of centrifugal melt spinning for the production of PEO-cinnamate fibers 
were investigated through observation and measurement of fiber morphology and 
diameter (Section 5.2).  
The material selected for producing the fibers is PEO, for its biocompatible and 
hydrophilic properties, as-spun, these fibers are not stable in aqueous environments. 
PEO-cinnamate as spun fibers are also not stable in aqueous environments. For the 
stabilization of fibers for contact to aqueous environments, such as in vitro and in 
vivo, a UV photocrosslinking treatment is used (Section 5.3). 
For the purpose of drug delivery, curcumin was loaded into the stabilized fibers via 
diffusion and the relationship between the loading concentration of curcumin and 
amount of loaded curcumin was determined (Section 5.4). The release of curcumin 
from the system in PBS was observed for 2 weeks to study the release kinetics 
(Section 5.5).  
To begin the assessment of the system, a free curcumin dose-dependence curve was 
determined with the human A549 cancer cell line (Section 5.6). This will allow for 
comparison to similar curcumin doses released from fibers. 
Figure 5.0 is a flow chart to outline the contents of this chapter.  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Figure 5.0: Flow-chart outlining contents of this chapter. 
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5.1. Synthesis and Chemical Characterization of Polymer 
5.1.1. Synthesis of PEO-cinnamate 
PEO-cinnamate was synthesized by functionalizing PEO with cinnamoyl chloride via 
an esterification reaction involving the hydroxyl groups of PEO and the reactive acyl 
chloride of cinnamoyl chloride with the presence of pyridine for deprotonation of 
PEO hydroxyls (Scheme 5.1). The product was then precipitated in diethyl ether, 
isolated and purified through vacuum filtration and diethyl ether rinsing and finally 
dried under house vacuum. 
Scheme 5.1 - Deprotonation of PEO (4.1) by pyridine followed by esterification with 
cinnamoyl chloride (4.2) to form PEO-cinnamate (4.3).  
5.1.2. Chemical Characterization of Product 
To demonstrate functionalization of PEO with cinnamoyl chloride, differential 
scanning calorimetry (DSC) was performed on the reactants and product of the 
synthesis reaction. DSC spectra show distinct single peaks for reactants and product. 
Melting temperatures for cinnamoyl chloride, PEO and PEO-cinnamate are 32°C, 
66°C and 61°C, respectively (Figure 5.1). The product has an intermediate melting 
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temperature demonstrating functionalization and the sharp single peaks demonstrate 
purity of the reactants and product. 
Figure 5.1: DSC thermograms of cinnamoyl chloride, PEO and PEO-cinnamate. 
Demonstrating the purity of the end product, meaning no residual free PEO or 
cinnamoyl chloride shown with a single peak in the DSC thermogram is important in 
the step of characterization. Although, cinnamoyl chloride has been shown to be non-
toxic in vivo [95].  
Up until this point, the functionalization of PEO has been presented as a one-sided 
reaction. However, considering the symmetry of PEO’s structure, there are three 
possible scenarios for this functionalization reaction. 1) unreacted, pure PEO (4.1), 2) 
single-sided functionalization (4.3) and 3) double-sided functionalization (4.4) 
(Figure 5.2). Although, having unreacted PEO is highly unlikely due to the reactivity 
and use of excess cinnamoyl chloride. The possibility of multiple end products 
require the processing and interpretation of FTIR and 1H-NMR spectra to take this 
into account. 
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Figure 5.2: Chemical structures of possible outcomes of the synthesis reaction. 
Next, FTIR was performed again on the reactants and product. The FTIR spectra of 
PEO shows an -OH stretch present in the 3600 cm-1 region and a strong sp3 C-H peak 
in the 3000 - 2840 cm-1 region (Figure 5.3). These peaks are in agreement with the 
chemical structure of PEO. The FTIR spectra of cinnamoyl chloride shows a strong 
aromatic C=C stretch in the 1660 - 1500 cm-1 region and the strength of the peak can 
be attributed to the conjugation of the aromatic ring (Figure 5.4). Finally, the FTIR 
spectra for PEO-cinnamate shows a strong sp3 C-H peak in the 3000 - 2840 cm-1 
region comparable to the peak in PEO, however, there is no -OH stretch detectable, 
indicating two-sided functionalization through the disappearance of this peak when 
reacted with cinnamoyl chloride (Figure 5.5). Other peaks such as C=O and C=C 
detected in the cinnamoyl chloride spectra are not clear in the PEO cinnamate spectra 
due to the molecular size of the PEO polymer. 
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Figure 5.3: FTIR spectra of PEO. An sp3 C-H stretch predominates and a -OH is 
visible. 
Figure 5.4: FTIR spectra of cinnamoyl chloride. Aromatic C=C stretch, C=O stretch 
and sp2 C-H stretch are present. 
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Figure 5.5: FTIR spectra of PEO-cinnamate functionalized on both ends. An sp3 
stretch is present and the -OH stretch is absent as compared to the PEO spectra. 
To further characterize the product, 1H-NMR was performed, and the 
functionalization of PEO with cinnamoyl chloride appeared successful, as evidenced 
by the shift in functionalized cinnamoyl peaks from 6.63, 6.66, 7.44, 7.48, 7.56, 7.82 
and 7.85 ppm (Figure 5.6A) for free cinnamoyl chloride to 6.45, 6.48, 7.38, 7.44, 
7.52, 7.68 and 7.71 ppm for functionalized cinnamate (Figure 5.6B). The peaks are 
further downfield for cinnamoyl chloride compared to PEO-cinnamate due to the 
highly electronegative chlorine atom in cinnamoyl chloride which attracts the 
electrons surrounding each proton and results in less shielding and an increase in 
chemical shift.  
Complete functionalization was achieved as determined by integration of the PEO 
multiplet at 3.65 ppm with respect to the doublet at 6.50 ppm associated with the 
hydrogen adjacent to the ester carbonyl of cinnamate (Figure 5.7). Additionally, there 
was no free cinnamoyl chloride as determined by the absence of those peaks (Figure 
5.6A).  
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Figure 5.6: NMR spectra of pure cinnamoyl chloride (A) and the synthesis product 
and chemical structure of PEO-cinnamate (B). A chemical shift difference between 
pure cinnamoyl chloride and functionalized PEO-cinnamate is present. 
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Figure 5.7: NMR spectra comparison of 4 hour (5.6B) and overnight (above) 
reaction times. 
There is more than one way to process NMR data in terms of which peaks to set as 
the reference for integration. For instance, any of the peaks could be set as the 
reference if their value was known to be accurate. In this case, the PEO peak could be 
set as the reference as the number of hydrogens of a 35 000 g/mol molecule could be 
calculated with reasonable accuracy as determined by the supplier. With this method, 
after reaction times of 4 hours, 6 hours and overnight, 81.0 - 92.5% of the PEO 
hydroxyls were functionalized with cinnamoyl chloride on two sides as suggested by 
the integration value between one and two for the reactions. And 100% of molecules 
had at least one side functionalized. 
This result also indicates that the shortest reaction time between PEO and cinnamoyl 
chloride of 4 hours is a sufficient amount of time to allow the reaction to proceed to 
completion. In the future, further optimization could be performed to further reduce 
this reaction time if desired. Another consideration would be the base used in 
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deprotonating the hydroxyls of PEO. A stronger base could make the reaction proceed 
at an even more efficient rate. However, with a stronger base such as triethylamine 
(TEA) an acid/base wash may be required to remove the excess base adding another 
step in the procedure.  
These results reiterate the DSC and FTIR findings that PEO has been fully 
functionalized with cinnamoyl chloride and that a pure product is possible to obtain. 
5.2. Characterization of Functionalized Fibers 
In order to demonstrate the utility of a cotton candy machine for the production of 
fibers as reported by other groups, we produced pure PEO fibers using an as-
purchased cotton candy machine and observed fiber morphology (Appendix A). We 
deemed the fiber quality produced was sufficiently promising to proceed with the 
investigation.  
One of the important parameters of centrifugal melt spinning is the melting point of 
the polymer. Melting point (Tm) of pure 35 000 g/mol PEO was determined to be 
66°C, in order to translate this process to PEO-cinnamate, the Tm was determined to 
be 61°C.  With a distinct Tm, PEO-cinnamate fibers were produced using an as-
purchased cotton candy machine, which was determined to spin at a fixed rate of 
~2300 RPM and were imaged with optical microscopy (Figure 5.8). The average 
fiber diameter was determined to be 28.9±13.3 µm and the fiber diameters had a 
normal distribution as shown in Figure 5.9. 
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Figure 5.8: Optical microscopy images of PEO-cinnamate fibers produced with the 
as-purchased cotton candy machine. 
Figure 5.9: Fiber diameter distribution of PEO-cinnamate fibers shown above 
produced using an as-purchased cotton candy machine. 
Although small fiber diameters are critical for tissue engineering applications as it 
influences cell morphology, migration and stem cell differentiation, the importance of 
fiber diameter for drug delivery is related to the release rate of drug from the fiber. 
For diffusion dependent fiber delivery systems, larger diameter fibers may have 
slower diffusion due to the diffusion distance from the core of the fiber. Also, the 
surface area to volume ratio is increased for smaller diameter fibers which may 
enhance drug release [96]. 
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The next fiber production step involved the modification of the spinning set-up. PEO-
cinnamate fibers produced using this modified centrifugal melt spinning at 6000 
RPM, 45 V for voltage controlled temperature and under ambient conditions with a 
newly designed spinneret. Images were taken with SEM (Figure 5.10). Fibers 
produced had a uniform morphology along the fibers and an average fiber diameter 
was determined to be 11.5±5.5 µm from analysis of 120 fibers of the sample. 
Figure 5.10: Scanning electron microscopy images of PEO-cinnamate fibers 
produced with modified system and newly designed spinneret at 150X (A-C) and 
350X (D) magnifications. Scale bars are 300 µm (A-C) and 100 µm (D). 
The fiber diameters were normally distributed as shown in (Figure 5.11A). The 
values are well described by a Gaussian curve (Figure 5.11B). Therefore, with 
modifications of the fiber spinning system, the average fiber diameter was reduced 
and the distribution was narrowed. Although the differences can not be directly 
A B
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compared given that the imaging modalities differ. 
Figure 5.11: Fiber diameter distribution of PEO-cinnamate fibers shown in A, 
average diameter of 11.5 ± 5.5 µm (n = 130). B presents fiber diameter frequencies 
(pink) in respect to a Gaussian curve (black). 
These results demonstrate the utility of centrifugal melt spinning for the rapid and 
facile production of uniform polymeric fibers. Also, the demonstration that fiber 
diameter was altered through the alteration of the spinneret, indicates the possibility 
of optimization of the process further to obtain a wide range of diameters by changing 
that parameter. Additionally, as reported by [48], this fiber production method is 
controlled by several parameters permitting the future optimization through changes 
in rotation speed, solution viscosity, environmental temperature and others. 
5.3. UV Crosslinking of Fibers 
The fibers were irradiated with a 365 nm UV lamp (Cole-Parmer, Canada) at a 
distance of 5 cm from the source, the shortest distance available with the stand. Using 
UV/Vis spectroscopy, it was shown that prior to UV exposure, C=C of cinnamate was 
intact, showing maximum absorbance at 277 nm. Also, PEO which does not possess 
the C=C shows no absorbance at 277 nm. First, crosslinking was demonstrated on 
thin films as a proof-of-concept for the time dependency on the degree of crosslinking 
(Figure 5.12). As the films are exposed to UV for 0, 0.5 and 1 hour, the peak 
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associated with C=C diminishes, indicating crosslinking. After success with the thin 
films, we applied this method to the fibers. As the fibers are exposed to 1, 2 and 4 
hours of UV, absorbance decreases, indicating breakage of the C=C and non-C=C 
bond formation suggesting crosslinking had occurred, measurements were made in 
triplicate and the variability is reflected by the error bars (Figure 5.13). To further 
demonstrate UV crosslinking of fibers, FTIR spectra of PEO-cinnamate before and 
after UV irradiation was obtained. A peak at 1640 cm-1 corresponding to C=C stretch 
of cinnamate moieties is reduced (Figure 5.14). Qualitative demonstration of 
stability, fibers embedded with curcumin were suspended in waters and centrifuged 
(Figure 5.17). A network is clearly visible as the pellet in the centrifuge tube. 
Figure 5.12: UV/Vis spectra of PEO-cinnamate thin films on quartz slides after 
various lengths (0, 0.5, 1 hour) of UV exposure. The peak at 277 nm is associated 
with C=C double of cinnamoyl chloride. 
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Figure 5.13: UV/Vis spectra of PEO-cinnamate fibers after various lengths (0, 1, 2 
and 4 hours) of UV exposure and pure PEO without irradiation. A peak at 277 nm 
associated with C=C in cinnamate is outlined. 
Figure 5.14: FTIR spectrum of PEO-cinnamate before (solid line —) and after 4 
hours of UV irradiation (dashed line - - ). 
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Crosslinking is essential for water soluble polymers such as PEO in order to stabilize 
the polymer for contact to aqueous environments such as any physiological 
environment. This set of results demonstrates quantitatively and qualitatively the 
crosslinking of PEO-cinnamate fibers to stabilize them in an aqueous environment. 
The peaks of UV/Vis spectra at 227 nm look diminished nearly to baseline of PEO, 
however, there is the possibility of some C=C bonds and uncrosslinked chains 
remaining. This would be due to steric hindrance, particularly related to the thickness 
of the film or fibrous mat.  
In the future, in order to increase crosslinking efficiency, a UV lamp emitting 
wavelengths closer 277 nm would be more appropriate. This would decrease the 
length of time required for crosslinking as the wavelength is closer to the absorption 
wavelength. 
5.4. Curcumin Loading 
One of the applications of the stabilized fibers is drug delivery. In order to 
demonstrate the utility of this material as a drug delivery carrier, investigation of 
loading and release kinetics was required. First, to determine that loading of curcumin 
into the fibers effectively occurred after soaking in an ethanolic curcumin solution, 
the sample was visually observed for a colour change and further analyzed with FTIR 
to identify the presence of functional groups associated with curcumin not present in 
the unloaded sample. A sample loaded with curcumin after the excess surface 
curcumin was washed off is shown in Figure 5.15. The bright yellow hue is visually 
apparent, indicating the presence of curcumin. However, to ensure that the curcumin 
was not present only on the surface of the swollen fibers, several rinses were 
performed until the run-off contained no detectable curcumin, suggesting surface 
curcumin was removed. FTIR analysis revealed a peak at 3425 cm-1 corresponding to 
the phenolic O-H stretch present in curcumin. A peak at 2883 cm-1 corresponding to 
aromatic C-H stretch and is present for both PEO-cinnamate containing and not 
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containing curcumin. A peak at 1635 cm-1 corresponding to the conjugated system for 
C=O stretch in curcumin was present. A peak at 1466 cm-1 corresponding to C-C 
stretch bond in the ring of aromatic groups of curcumin and PEO-cinnamate were 
present (Figure 5.16). Thus, it was determined that curcumin was embedded within 
the fiber. 
Figure 5.15: Image of wet bulk fibers loaded with curcumin with a visible yellow 
hue after washing to remove surface curcumin. 
Figure 5.16: FTIR spectrum of crosslinked PEO-cinnamate with (orange) and 
without (black) curcumin incorporation. 
15001800210024002700300033003600
0.00
0.05
0.10
Fibers without
curcumin
Fibers with 
curcumin
3425
2883
1635
1466
Wavenumber (cm-1)
A
bs
or
ba
nc
e 
(a
.u
.)
!50
Figure 5.17: Fibers loaded with curcumin in water (left) and isolated via 
centrifugation (right) to demonstrate the stability of the fibers in an aqueous 
environment. 
To determine whether the amount of loaded curcumin was tuneable, various 
concentrations of curcumin in ethanol, 1, 3 and 5 mg/ml were used for loading. It was 
determined that as loading concentration increased, curcumin loading increased 
(Figure 5.18).  In a loading concentration of 1, 3 and 5 mg/ml, 200 mg of fibers 
carried 23.89±2.29, 37.32±0.63, 54.32±0.62 µg, respectively. Thus, the amount of 
curcumin loaded is tuneable based on the curcumin loading concentration and is 
related to the amount of fibers by mass. To ensure curcumin was maximally drawn 
out of the fibers, extraction continued until curcumin was undetectable in the 
supernatant using UV/Vis spectrophotometry measurements at 427 nm, the 
absorbance wavelength for curcumin [97]. Representative images of the fibers during 
the first and last wash extractions are shown in Figure 5.19. 
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Figure 5.18: Amount of curcumin loaded relative to the concentration of curcumin 
loading solution. 
Figure 5.19: Curcumin loaded fibers during the first extraction (left) and last 
extraction (right) the red circle identifying the bulk of the fibers. 
5.5. In vitro Curcumin Releases 
Loaded fibers were placed in PBS in a 37°C shaking water bath for 7 and 14 days for 
fibers loaded in 1 mg/ml and 3 mg/ml solutions, respectively. These end points were 
selected as consecutive measurements at these time points indicated a plateau, with 
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no further release. Curcumin release was observed and a release profile was obtained 
to study the type of release from this polymeric system. It was found that the 
cumulative amount of curcumin release is dependent on the amount of curcumin 
loaded as seen with the raw data in Figure 5.20. Also, the release profiles do not 
significantly differ from each other as demonstrated with a two-way ANOVA, 
comparing the two release curves once scaled based on the final cumulative amount 
of curcumin extracted (Figure 5.21), p = 0.6095, indicating a non-significant 
difference in the release profiles.  
Figure 5.20: Raw data release profiles of PEO-cinnamate fibers loaded in 1 mg/ml 
(green) and 3 mg/ml (blue) loading concentrations. 
To further characterize the release, using mathematical models to describe the data 
may be useful. The empirical model described by Ritger and Peppas [98], compares 
the release profile to a power law. Two fitting parameters k and n are used to fit time, 
t, to cumulative release from the system, Mt/M∞. Mt/M∞=ktn, where Mt/M∞ is the 
amount of drug released, k is the kinetic constant, t is the time for release and n is the 
diffusional constant. The n-values are of significant importance for relating the 
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system geometry to the drug release mechanism as shown in Table 3. The n-values 
for both fibers loaded in 1 mg/ml solution and 3 mg/ml solution when fitted to the 
empirical model, diffusion exponent were 0.48 ± 0.14 and 0.31 ± 0.02,  respectively. 
The fit of this model was reasonable with R2 values of 0.86 for 1 mg/ml and 0.99 for 
3 mg/ml loading. 
Figure 5.21: Data scaled based on maximum curcumin extracted through release in 
PBS. Data fitted with Power Law for Mt/Mi ≤ 0.6. 
The diffusion coefficient, n, for the 1 mg/ml, according to this model, falls within the 
range of anomalous (non-Fickian) transport (Table 3). For the 3 mg/ml loading, 
according to this model, does not fall within any of the ranges described. This could 
be due imperfections in the fiber and thus variable release unpredicted by the model. 
Further characterization of loaded fiber morphology would be useful. As determined 
from the two-way ANOVA, these two plots are not significantly different from each 
other, and thus should exhibit similar non-linear fits. Also, these tests were performed 
in triplicate, and with further optimization and replicates, the calculated values will 
become more accurate. Additionally, this data could be fitted to equation 5 of chapter 
2. This would allow for the determination of D, the diffusion coefficient which would 
best describe the diffusivity of curcumin from the system.  
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Table 3: Diffusion exponent and drug release mechanisms of different geometries 
5.6. Effect of Free Curcumin on Cells 
The A549 cell line was selected based on literature findings and similar intracellular 
targets to squamous cell carcinomas [99-101]. Although the A549s are not derived 
from a SCC, the intracellular targets of curcumin are more important and relevant for 
cell testing. It has been established that drug sensitivity is not tissue-specific when 
testing cancer cell lines [102].  
To determine the dose-dependence of curcumin on cell growth inhibition, an initial 
range of curcumin concentrations ranging from 0 - 100 uM was selected to treat cells. 
This starting range was selected based on previous work [99-101].  The initial range 
of concentrations revealed 100 % effectiveness with concentrations of 15 µM and 
above (Figure 5.22). This value is significantly different from the values previously 
reported. In the literature, the IC50 value reported is 18 µM [103]. Possible factors 
contributing to this discrepancy include curcumin purity, and light and heat exposure 
to samples as curcumin is both light and heat sensitive.  
Dose-dependent growth inhibition was observed and the IC10, IC50 and IC90 were 
determined from these curves (Figures 5.22 and 5.23) to be 1.87 ± 0.32 µM , 7.28 ± 
0.34 µM, 13.37 ± 0.53 µM, respectively. These values will be useful in determining 
the amount of curcumin to load into the stabilized PEO-cinnamate fiber drug carrier 
for preliminary studies. Also, these values may be used as bench marks for comparing 
the effect of curcumin released from fibers versus free curcumin, as the system may 
Drug release 
mechanism
Diffusion Exponent, n
Thin film Cylinder Sphere
Fickian 0.5 0.45 0.43
Anomalous (non-
Fickian) transport
0.5<n<1.0 0.45<n<0.89 0.43<n<0.85
Case-II Transport 1.0 0.89 0.85
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increase the bioavailability and thus have an increase effect. 
Figure 5.22: Broad range free curcumin dose-response curve. 
 
Figure 5.23: Higher resolution free curcumin dose-response curves original batch 
(blue), fresh batch (orange). 
5.7. Effect of Curcumin Loaded PEO-Cinnamate Fibers 
Using the results from the free curcumin dose-dependency study, calculations are 
prepared as a guideline for moving forward with the study of loaded curcumin on 
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these cells. Calculations for loading equivalent amounts of curcumin for in vitro 
studies are shown below. 
IC 10: 
IC 50: 
 
IC 90: 
As shown with the range achieved for the loading concentration and actual amount of 
curcumin loaded into the stabilized fibers (Figure 5.18), it is possible for these 
amounts of curcumin to be incorporated into the stabilized fibers.  
!57
6. CONCLUSIONS 
We have demonstrated the synthesis of a photosensitive polymer that can undergo UV 
photocrosslinking for aqueous stability following fiber fabrication using a modified 
cotton candy machine. Ultimately, this fiber fabrication method presents the potential 
for a highly scalable method to produce fibers for biomedical purposes, such as drug 
delivery. The utility of these stabilized fibers for carrying and delivering curcumin 
has also been demonstrated. And we have demonstrated the relationship between the 
curcumin loading concentration and amount of curcumin actually loaded. 
Additionally, the effect of free curcumin in a dose-dependent manner on an A549 
cancer cell line has been investigated. Thus, this stabilized polymeric system has the 
potential to carry a sufficient amount of curcumin for an effective reduction of cancer 
cell growth. 
7. FUTURE DIRECTIONS 
There are several future directions and experiments that can follow this work. Some 
of the major material components to be explored are the swelling and degradation 
properties of the system. These two parameters effect drug release, are important to 
define for polymer systems and the characterization of which is essential in fully 
understanding the system. To further investigate the release of curcumin in vitro, in 
place of PBS, simulated body fluid consisting of proteins would be of interest to 
determine if the presence of proteins would effect the release of curcumin [104]. 
These studies could be better predictors of how this system would perform in vivo. In 
addition to studying the release of curcumin in vitro, the study of the effect of 
curcumin is important in establishing a relationship between the drug and cells. One 
study could be of the antioxidant activity of curcumin, post-release from the 
polymeric system to ensure the activity remains intact. The 1,1’-diphenyl-2-
picrylhydrazyl (DPPH) assay is a possibility and has been shown to be effective in 
detecting the antioxidant activity of curcumin [96]. The effect of free curcumin on 
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A549 cells have been established in the work and the concentrations of such an effect 
has been measured. These values can be used as a guideline for the study of the effect 
of curcumin loaded into the stabilized fibers on the cells. It would also be of interest 
to perform these studies on another cell line with similar cellular targets to see if the 
effects are comparable. And of course, in vivo studies with an appropriate animal 
model would be an important step in evaluating the efficacy of this system after the 
optimization steps with the in vitro studies. These experiments would determine the 
anti-cancer efficacy of the system and any system related toxicity. One way to study 
this in a controlled experiment would be to treat areas of nude animal skin with a 
mutation inducing chemical such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and 
at various times post-treatment of TPA apply the polymeric system for various lengths 
of time and evaluate the changes in the skin macroscopically and microscopically 
with histology.  
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APPENDICES 
Appendix A: As-spun PEO fibers fabricated using a modified cotton candy machine. 
Scale bar for the right image is 50 µm. 
Appendix B: Fluorescence images of stabilized PEO-cinnamate fibers dry and in 
water. Although the certainty of whether these two fibers are identical, there is a 
visible size difference. Scale bars for both images at 100 µm.  
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Appendix C: UV/Vis calibration curve for curcumin in ethanol. 
Appendix D: UV/Vis calibration curve for curcumin in phosphate buffered saline. 
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